Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 16, 2001
Grant Date -
N/A
app pub date -
Oct 6, 1998
filing date -
Apr 25, 1996
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully